Lexicon Pharmaceuticals, INC. (LXRX) — 10-Q Filings
All 10-Q filings from Lexicon Pharmaceuticals, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Lexicon Narrows Losses on Novo Nordisk Deal, Cuts Spending
— Nov 6, 2025 Risk: medium
Lexicon Pharmaceuticals, Inc. reported a significant reduction in net loss for the nine months ended September 30, 2025, decreasing to $34.8 million from $166.6 -
Lexicon's Losses Widen Amid Rising R&D Costs
— Aug 6, 2025 Risk: high
LEXICON PHARMACEUTICALS, INC. reported a net loss of $38.2 million for the three months ended June 30, 2025, a significant increase from the $29.5 million net l - 10-Q Filing — May 14, 2025
-
Lexicon Pharmaceuticals Q3 Expenses Decline
— Nov 13, 2024 Risk: medium
Lexicon Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses of $71.7 million f - 10-Q Filing — Aug 2, 2024
-
Lexicon Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024
— May 2, 2024 Risk: low
LEXICON PHARMACEUTICALS, INC. (LXRX) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Lexicon Pharmaceuticals, Inc. filed a 10-Q report for the peri
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX